ADMA Biologics

ADMA · NASDAQ

$11.23+$0.16 (+1.45%)TodayMarket closed ·
Prev close $11.07

Latest news

  • Press releasePRNewswire

    Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

  • Press releasePRNewswire

    Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

  • Press releasePRNewswire

    ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA

  • Press releasePRNewswire

    ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law

  • Press releasePRNewswire

    Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

  • Press releasePRNewswire

    ADMA Biologics, Inc. Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

  • Press releaseBusiness Wire

    CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

  • Press releasePRNewswire

    ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline

  • Press releasePRNewswire

    DEADLINE NEXT WEEK: Hagens Berman Advises ADMA Biologics, Inc. Investors to Contact the Firm Before August 10, 2026

  • Press releaseBusiness Wire

    ADMA Biologics 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA

  • Press releaseGlobe Newswire

    ADMA 3-DAY DEADLINE ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– Hagens Berman

  • Press releaseGlobe Newswire

    ADMA BIOLOGICS CLASS ACTION DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Urges ADMA Biologics, Inc. Stockholders to Contact the Firm Regarding Their Rights Before August 10th

  • Press releaseBusiness Wire

    ADMA Biologics Deadline: Rosen Law Firm Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm – ADMA

  • Press releasePRNewswire

    MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

  • Press releaseGlobe Newswire

    $ADMA Court News: ADMA Biologics Securities Fraud Class Action Deadline is Imminent – Contact BFA Law before August 10

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA

  • Press releasePRNewswire

    ADMA Biologics, Inc. Deadline: ADMA Investors with Losses in Excess of $100K Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

  • Press releaseGlobe Newswire

    MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - ADMA

  • Press releaseGlobe Newswire

    DEADLINE ALERT for FUTU, FSLR, BRCB, ADMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

  • Press releaseGlobe Newswire

    Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

  • Press releaseGlobe Newswire

    DEADLINE NEXT WEEK: Hagens Berman Advises ADMA Biologics, Inc. Investors to Contact the Firm Before August 10, 2026

  • News

    ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate

  • Press releaseGlobe Newswire

    ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releaseGlobe Newswire

    DEADLINE NEXT WEEK: Berger Montague Advises ADMA Biologics, Inc. (NASDAQ: ADMA) Investors to Contact the Firm Before August 10, 2026

  • Press releasePRNewswire

    Robbins LLP Reminds ADMA Investors of the August 10, 2026 Lead Plaintiff Deadline; Contact the Firm for Information About Recovering Your Losses

  • Press releaseGlobe Newswire

    ADMA Legal News: ADMA Biologics Hit with Securities Fraud Class Action over Alleged Misrepresentations about its Revenue – Contact BFA Law

  • Press releasePRNewswire

    ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

  • Press releasePRNewswire

    ADMA DEADLINE: The Gross Law Firm Reminds ADMA Biologics, Inc. Investors of Upcoming Securities Class Action Deadline

  • Press releaseGlobe Newswire

    DEADLINE ALERT for BTGO, VIA, Z, ADMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

  • Press releaseGlobe Newswire

    ADMA Shareholder Alert: ADMA BIOLOGICS, INC. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky

  • Press releaseGlobe Newswire

    Important Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); Insulet Corporation (NASDAQ: PODD); Intuit Inc. (INTU); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf

  • Press releaseGlobe Newswire

    Important Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); Commvault Systems, Inc. (NASDAQ: CVLT); Erasca, Inc. (NASDAQ: ERAS); and Hub Group, Inc. (NASDAQ: HUBG): Grabar Law Office is Investigating Claims on Your Behalf

  • Press releaseGlobe Newswire

    DEADLINE ALERT for VIA, Z, ADMA, and ERAS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

  • Press releaseGlobe Newswire

    Important Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); GeneDx Holdings Corp. (NASDAQ: WGS); Navan, Inc. (NASDAQ: NAVN); and New Era Energy & Digital, Inc. (NASDAQ: NUAI) (FKA New Era Helium (NASDAQ: NEHC)): Grabar Law Office is Investigating Claims on Your Behalf

  • Press releaseGlobe Newswire

    DEADLINE ALERT for BTGO, VIA, Z, ADMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

  • Press releaseGlobe Newswire

    DEADLINE ALERT for VIA, Z, and ADMA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

  • Press releaseGlobe Newswire

    DEADLINE ALERT for BTGO, VIA, Z, ADMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

  • Press releasePRNewswire

    ADMA Shareholder Alert: ADMA BIOLOGICS, INC. Securities Class Action Lawsuit - Investors Should Contact SueWallSt

  • NewsSurbhi Jain

    Stanley Druckenmiller Dumps Amazon And Alphabet While Loading Up On Commodities, Argentina And Biotech

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • NewsAvi Kapoor

    Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Wednesday's After-Market Session

  • News

    Earnings Scheduled For May 6, 2026

  • News

    ADMA Biologics Q1 Adj. EPS $0.17 Misses $0.20 Estimate, Sales $114.493M Miss $141.800M Estimate

  • Press releaseGlobe Newswire

    ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

  • NewsVandana Singh

    ADMA Biologics Slams Short Seller Claims, Highlights Strong Demand

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.